NO20064212L - Piperidinyl som retter seg mot forbindelser som selektivt binder integriner - Google Patents

Piperidinyl som retter seg mot forbindelser som selektivt binder integriner

Info

Publication number
NO20064212L
NO20064212L NO20064212A NO20064212A NO20064212L NO 20064212 L NO20064212 L NO 20064212L NO 20064212 A NO20064212 A NO 20064212A NO 20064212 A NO20064212 A NO 20064212A NO 20064212 L NO20064212 L NO 20064212L
Authority
NO
Norway
Prior art keywords
piperidinyl
selectively bind
bind integrins
targets compounds
targets
Prior art date
Application number
NO20064212A
Other languages
English (en)
Inventor
Bruce E Maryanoff
Jr Robert Anthony Galemmo
Bart De Corte
William A Kinney
Shyamali Ghosh
Li Liu
Livia Brunner
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NO20064212L publication Critical patent/NO20064212L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Det beskrives syntese og biologisk anvendelse av piperidinoylkarboksylsyrer som er integrin antagonistaffinitetsdeler med formel (I) og formel (II). Affinitetsdelene kan benyttes med billedgivende midler eller liposomer for å sikte inn på celler som uttrykker avß3, avß5 eller avß6 integrinreseptorer.
NO20064212A 2004-02-18 2006-09-18 Piperidinyl som retter seg mot forbindelser som selektivt binder integriner NO20064212L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/782,060 US20040224986A1 (en) 2002-08-16 2004-02-18 Piperidinyl targeting compounds that selectively bind integrins
PCT/US2004/009465 WO2005082889A1 (en) 2004-02-18 2004-03-29 Piperidinyl targeting compounds that selectively bind integrins

Publications (1)

Publication Number Publication Date
NO20064212L true NO20064212L (no) 2006-11-15

Family

ID=34911385

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20064212A NO20064212L (no) 2004-02-18 2006-09-18 Piperidinyl som retter seg mot forbindelser som selektivt binder integriner

Country Status (19)

Country Link
US (3) US20040224986A1 (no)
EP (1) EP1718635A1 (no)
JP (1) JP2007523907A (no)
KR (1) KR20070010125A (no)
CN (1) CN101023072A (no)
AU (1) AU2004316476A1 (no)
BR (1) BRPI0418552A (no)
CA (1) CA2556768A1 (no)
EA (1) EA200601517A1 (no)
EC (1) ECSP066778A (no)
HR (1) HRP20060298A2 (no)
IL (1) IL177502A0 (no)
IS (1) IS8532A (no)
ME (1) MEP48908A (no)
MX (1) MXPA06009503A (no)
NO (1) NO20064212L (no)
RS (1) RS20060470A (no)
WO (1) WO2005082889A1 (no)
ZA (1) ZA200607756B (no)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040224986A1 (en) 2002-08-16 2004-11-11 Bart De Corte Piperidinyl targeting compounds that selectively bind integrins
US8986650B2 (en) 2005-10-07 2015-03-24 Guerbet Complex folate-NOTA-Ga68
CA2625196C (fr) 2005-10-07 2016-04-05 Guerbet Composes comprenant une partie de reconnaissance d'une cible biologique, couplee a une partie de signal capable de complexer le gallium
ES2474165T3 (es) * 2007-10-30 2014-07-08 Janssen Pharmaceutica N.V. Proceso enantioselectivo para preparar un ácido alcanoico sustituido
WO2009114776A2 (en) * 2008-03-14 2009-09-17 Visen Medical, Inc. Integrin targeting agents and methods of using same
EP2300437B1 (en) 2008-06-05 2013-11-20 Glaxo Group Limited Benzpyrazol derivatives as inhibitors of pi3 kinases
EP2280705B1 (en) 2008-06-05 2014-10-08 Glaxo Group Limited Novel compounds
JP5502077B2 (ja) 2008-06-05 2014-05-28 グラクソ グループ リミテッド 新規な化合物
EP2406255B1 (en) 2009-03-09 2015-04-29 Glaxo Group Limited 4-oxadiazol-2-yl-indazoles as inhibitors of pi3 kinases
AR076435A1 (es) 2009-04-30 2011-06-08 Glaxo Group Ltd Compuestos de indazoles sustituidos, composiciones farmaceuticas que los contienen y procesos de obtencion de los mismos
GB201018124D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
GB201305668D0 (en) 2013-03-28 2013-05-15 Glaxosmithkline Ip Dev Ltd Avs6 Integrin Antagonists
EP3050878B1 (en) 2013-09-24 2021-10-27 FUJIFILM Corporation Novel nitrogen-containing compound or salt thereof, or metal complex thereof
GB201417002D0 (en) * 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compound
GB201417094D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417011D0 (en) * 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417018D0 (en) * 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201604680D0 (en) 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds
GB201604681D0 (en) * 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds
WO2019210200A1 (en) * 2018-04-27 2019-10-31 Arrowhead Pharmaceuticals, Inc. Integrin targeting ligands and uses thereof
IL305752A (en) * 2021-03-10 2023-11-01 Dice Molecules Sv Inc INTEGRIN INHIBITORS OF ALPHA V BETA 6 AND ALPHA V BETA 1 AND THEIR USES
CN120282949A (zh) * 2023-09-28 2025-07-08 云合智药（苏州）生物科技有限公司 靶向整合素的化合物及其在RNAi剂中的应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN148482B (no) * 1977-06-03 1981-03-07 Pfizer
WO1993017715A1 (en) * 1992-03-05 1993-09-16 Board Of Regents, The University Of Texas System Diagnostic and/or therapeutic agents, targeted to neovascular endothelial cells
US5474765A (en) * 1992-03-23 1995-12-12 Ut Sw Medical Ctr At Dallas Preparation and use of steroid-polyanionic polymer-based conjugates targeted to vascular endothelial cells
US5902795A (en) * 1992-06-16 1999-05-11 Trustees Of Tufts College Oligosaccharides reactive with hyaluronan-binding protein and their methods of use
US5340798A (en) * 1992-10-14 1994-08-23 Merck & Co., Inc. Fibrinogen receptor antagonists
US5753659A (en) * 1993-03-29 1998-05-19 Zeneca Limited Heterocyclic compouds
DE69623455T2 (de) 1995-04-19 2003-01-16 Schneider (Usa) Inc., Plymouth Beschichteter dilatator zur abgabe eines arzneistoffs
DE19613933A1 (de) 1996-04-06 1997-10-09 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
US6056973A (en) * 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
US5919792A (en) * 1996-10-30 1999-07-06 Merck & Co., Inc. Integrin antagonists
CA2272090A1 (en) 1996-12-09 1998-06-18 Matthew J. Fisher Integrin antagonists
PE122699A1 (es) 1997-09-19 2000-02-12 Smithkline Beecham Corp Antagonistas de receptores de vitronectina
US6211191B1 (en) * 1997-12-17 2001-04-03 Merck & Co., Inc. Integrin receptor antagonists
WO1999031061A1 (en) 1997-12-17 1999-06-24 Merck & Co., Inc. Integrin receptor antagonists
ATE295369T1 (de) 1998-03-31 2005-05-15 Bristol Myers Squibb Pharma Co Pharmazeutika zur bildgebung der angiogenischen krankheiten
UA71586C2 (en) 1998-12-04 2004-12-15 Smithkline Beecham Corp A vitronectin receptor antagonist
EP1140864A2 (en) 1998-12-18 2001-10-10 Du Pont Pharmaceuticals Company Vitronectin receptor antagonist pharmaceuticals
DE69936148T2 (de) 1998-12-18 2008-01-24 Bristol-Myers Squibb Pharma Co. Vitronektinrezeptorantagonist-arzneimittel
CA2349501A1 (en) 1998-12-18 2000-06-22 Du Pont Pharmaceuticals Company Quinolone vitronectin receptor antagonist pharmaceuticals
JP2002537260A (ja) 1999-02-17 2002-11-05 メルク エンド カムパニー インコーポレーテッド αＶインテグリン受容体拮抗薬としてのジベンゾ−アゼピン誘導体
IL145941A (en) * 1999-04-28 2007-08-19 Univ Texas Compositions and methods for cancer treatment by selectively inhibiting vegf
DK1187592T3 (da) 1999-06-02 2007-11-05 Merck & Co Inc Alfa v-integrinreceptorantagonister
DE60021521T4 (de) 1999-09-29 2006-09-21 Ortho-Mcneil Pharmaceutical, Inc. Isonipecotamide zur behandlung von integrin vermittelten störungen
WO2001083740A2 (en) * 2000-05-04 2001-11-08 Avi Biopharma, Inc. Splice-region antisense composition and method
US6776796B2 (en) * 2000-05-12 2004-08-17 Cordis Corportation Antiinflammatory drug and delivery device
US6933304B2 (en) 2000-06-15 2005-08-23 Pharmacia Corporation Heteroarylalkanoic acids as integrin receptor antagonists
US20040009465A1 (en) 2002-07-12 2004-01-15 Voraphat Luckanatinvong Shelf life indicator components for fresh cut fruits and vegetables responding to carbondioxide
JP4554364B2 (ja) * 2002-08-16 2010-09-29 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ インテグリンと選択的に結合するピペリジニル化合物
US20040224986A1 (en) 2002-08-16 2004-11-11 Bart De Corte Piperidinyl targeting compounds that selectively bind integrins

Also Published As

Publication number Publication date
US7879881B2 (en) 2011-02-01
AU2004316476A1 (en) 2005-09-09
US20040224986A1 (en) 2004-11-11
CN101023072A (zh) 2007-08-22
RS20060470A (sr) 2008-11-28
US20080058359A1 (en) 2008-03-06
EP1718635A1 (en) 2006-11-08
KR20070010125A (ko) 2007-01-22
CA2556768A1 (en) 2005-09-09
US20110092528A1 (en) 2011-04-21
WO2005082889A1 (en) 2005-09-09
US8110683B2 (en) 2012-02-07
MXPA06009503A (es) 2007-04-19
MEP48908A (bs) 2011-02-10
BRPI0418552A (pt) 2007-05-22
IS8532A (is) 2006-09-15
JP2007523907A (ja) 2007-08-23
IL177502A0 (en) 2006-12-10
EA200601517A1 (ru) 2007-06-29
ECSP066778A (es) 2006-11-16
HRP20060298A2 (hr) 2007-03-31
ZA200607756B (en) 2008-06-25

Similar Documents

Publication Publication Date Title
EA201000558A1 (ru) Производные имидазола
AU2009236256A8 (en) Small molecule inhibitors of the pleckstrin homology domain and methods for using same
BRPI0510170B8 (pt) composto, composição farmacêutica para o tratamento de doenças mediadas pelo receptor muscarínico de acetilcolina e uso do composto
NO20081287A (no) Brenselsammensetning og fremgangsmåte for å fremstille denne
CO6160299A2 (es) Solvatos cristalinos y complejos de derivados de (1s)-1,5-anhidro-1-c-(3-((fenil)metil)fenil)-d-glucitol con aminoácidos como inhibidores sglt2 para el tratamiento de diabetes.
ATE505489T1 (de) Tgf-beta-1-spezifische antikörper
TW200744588A (en) Pharmaceutical composition for external use
EP2248869A3 (de) Verbindungen für organische elektronische Vorrichtungen
MY145462A (en) Pharmaceutical combinations of an angiotensin receptor antagonist and an nep inhibitor
IL181529A0 (en) Diagnostic compounds
CY1110498T1 (el) Παραγωγα πυραζολης ως αναστολεις των κινασων τυροσινης υποδοχεα
WO2007084264A3 (en) Methods for myocardial imaging
EA201000550A1 (ru) Производные тиазола
EP2345043A4 (en) WASTE STORAGE CONTAINERS AND COMPOSITIONS THEREFOR
WO2006072615A3 (en) Triazolophthalazines as pde2-inhibitors
EA200601517A1 (ru) Нацеливающие пиперидинилсодержащие соединения, селективно связывающие интегрины
EP2631248A3 (en) Treatment of tumors using specific anti-L1 antibody
BRPI0617479A2 (pt) método e composição útil para manter ou melhorar a saúde gastrintestiinal de um animal, kit, meio para comunicação de informações ou instruções, e, uso de uma composição
EA200970124A1 (ru) Производные 2-арилиндола в качестве ингибиторов npges-1
ZA200801875B (en) Isoquinolines as IGF-IR inhibitors
EA200801414A1 (ru) Кальцилитические соединения
ATE487721T1 (de) Triaza-benzoäeüazulenderivate zur behandlung von tumoren
WO2006129828A3 (en) Target substance capturing molecule
EA200901180A1 (ru) Производные тетрагидрохинолина и их применение для лечения злокачественного новообразования
WO2007007207A8 (en) Pharmaceutical compositions of 3, 5 -bis (arylidene) -4 -piperidones and analogues there of for modulating cell proliferation

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application